[go: up one dir, main page]

CL2016001001A1 - Profármacos y moduladores de receptores nmda, sales y usos de estos - Google Patents

Profármacos y moduladores de receptores nmda, sales y usos de estos

Info

Publication number
CL2016001001A1
CL2016001001A1 CL2016001001A CL2016001001A CL2016001001A1 CL 2016001001 A1 CL2016001001 A1 CL 2016001001A1 CL 2016001001 A CL2016001001 A CL 2016001001A CL 2016001001 A CL2016001001 A CL 2016001001A CL 2016001001 A1 CL2016001001 A1 CL 2016001001A1
Authority
CL
Chile
Prior art keywords
modulators
prodrugs
salts
nmda receptors
syndrome
Prior art date
Application number
CL2016001001A
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of CL2016001001A1 publication Critical patent/CL2016001001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPUESTOS MACROCICLICOS DERIVADOS DE PEPTIDILO SUSTITUIDOS, MODULADORES DEL RECEPTOR NMDA; COMPOSICION FARMACEUTICA; Y SU USO PARA TRATAR AUTISMO, DEPRESION, EPILEPSIA, DEMENCIA ASOCIADA AL SIDA, ATROFIA MULTISITEMICA, PARALISIS SUPRANUCLEAR PROGRESIVA, ATAXIA DE FRIEDRICH, SINDROME DE DOWN, SINDROME X FRAGIL, ENTRE OTROS.
CL2016001001A 2013-10-28 2016-04-27 Profármacos y moduladores de receptores nmda, sales y usos de estos CL2016001001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28

Publications (1)

Publication Number Publication Date
CL2016001001A1 true CL2016001001A1 (es) 2016-12-16

Family

ID=53004986

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016001001A CL2016001001A1 (es) 2013-10-28 2016-04-27 Profármacos y moduladores de receptores nmda, sales y usos de estos
CL2020002247A CL2020002247A1 (es) 2013-10-28 2020-08-31 Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002247A CL2020002247A1 (es) 2013-10-28 2020-08-31 Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016)

Country Status (15)

Country Link
US (2) US9745342B2 (es)
EP (2) EP3564256A1 (es)
JP (1) JP6603668B2 (es)
KR (1) KR20160077153A (es)
CN (2) CN105764522A (es)
AU (2) AU2014342624A1 (es)
BR (1) BR112016009443A8 (es)
CA (1) CA2928701A1 (es)
CL (2) CL2016001001A1 (es)
IL (1) IL245302B (es)
MX (2) MX378668B (es)
RU (1) RU2016119830A (es)
SA (1) SA516371037B1 (es)
SG (2) SG10201810496XA (es)
WO (1) WO2015065891A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3598971T3 (pl) 2013-01-22 2024-09-09 Vistagen Therapeutics, Inc. Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
CA3033564A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Acetyl-leucine for neurodegenerative diseases
CN116082461B (zh) * 2022-10-14 2023-11-14 浙江大学 一种具有抗菌活性的小分子肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263858A1 (en) * 2004-09-14 2009-10-22 Shionogi & Co., Ltd. Process for synthesis of mucin-type peptides and muc1-related glycopeptides
CA2686827C (en) * 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
ES2398310T3 (es) * 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
CN102186883B (zh) * 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
JP2012503025A (ja) * 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド 精製されたポリペプチド組成物を調製するための方法
WO2011100585A1 (en) * 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP6035326B2 (ja) 2011-04-27 2016-11-30 ノースウェスタン ユニバーシティ アルツハイマー病、ハンチントン病、自閉症及びその他の疾患を治療する方法

Also Published As

Publication number Publication date
SG10201810496XA (en) 2018-12-28
US20180127466A1 (en) 2018-05-10
AU2020201109A1 (en) 2020-03-05
AU2014342624A1 (en) 2016-06-02
CL2020002247A1 (es) 2021-02-05
RU2016119830A3 (es) 2018-07-02
MX2016005510A (es) 2017-01-06
US9745342B2 (en) 2017-08-29
EP3062810A4 (en) 2017-05-03
MX2021000029A (es) 2021-03-25
IL245302A0 (en) 2016-06-30
RU2016119830A (ru) 2017-12-04
KR20160077153A (ko) 2016-07-01
JP6603668B2 (ja) 2019-11-06
CA2928701A1 (en) 2015-05-07
EP3062810A1 (en) 2016-09-07
MX378668B (es) 2025-03-10
WO2015065891A1 (en) 2015-05-07
CN112321678A (zh) 2021-02-05
US20160244485A1 (en) 2016-08-25
US10590167B2 (en) 2020-03-17
JP2016537413A (ja) 2016-12-01
CN105764522A (zh) 2016-07-13
BR112016009443A8 (pt) 2020-03-24
SA516371037B1 (ar) 2018-05-16
SG11201603376UA (en) 2016-05-30
IL245302B (en) 2020-05-31
EP3564256A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
GT201500093A (es) Moduladores de quinolinilo unidos a metileno de ror- gamma-t
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2016001415A1 (es) Composiciones farmacéuticas que comprenden fumarato de dimetilo
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CL2015002655A1 (es) Moduladores de p2x7
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
MX2017011307A (es) Compuestos de 4,6-diamino-pirido[3,2-d]pirimidina moduladores del receptor tipo toll.
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
UY34832A (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
EA201790461A1 (ru) Композиции внеклеточного матрикса
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
CL2017000716A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
MX378866B (es) Composiciones de azucar para la formacion de comprimidos por compresion directa.